Brief: Hutchmed (China) Says Ipsen Initiates Market Withdrawal And Recall Of Tazverik In China
09/03/2026 17:12
March 9 (Reuters) - HUTCHMED (China) Ltd 0013.HK: IPSEN INITIATES MARKET WITHDRAWAL AND RECALL OF TAZVERIK IN CHINA WITHDRAWS AND RECALLS TAZVERIK IN CHINA, HONG KONG, MACAU; ENDS ALL CLINICAL TRIALS ІPSEN HAS INFORMED HUTCHMED THAT IT IS VOLUNTARILY WITHDRAWING TAZVERІK IN US Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation